Flecainide acetate, a fluorinated local anesthetic analogue of procainamide synthesized in 1972, has recently become available as an oral agent for the management of ventricular arrhythmias.
Flecainide acetate is an oral antiarrhythmic agent recently approved in the United States for the management of ventricular arrhythmias.
FLECAINIDE acetate (Tambocor, Riker Laboratories) has recently become available in this country for the management of ventricular arrhythmias. The synthesis of flecainide in 1972 was the culmination of a systematic search for fluorinated local anesthetic analogues of procainamide (Fig. 1).1 Early screening experiments showed that this structure, N-(2-Piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide, was active in a variety of animal models of arrhythmia.2 Clinical testing of the agent began in 1975. Only oral flecainide is currently available, although an intravenous form is under investigation.Flecainide is the first of a number of agents with similar electrophysiologic properties to be approved in the United . . .
Roden et al. (Thu,) conducted a review in Ventricular arrhythmias. Flecainide acetate was evaluated. Flecainide acetate, a fluorinated local anesthetic analogue of procainamide synthesized in 1972, has recently become available as an oral agent for the management of ventricular arrhythmias.